2020 American Transplant Congress
Waiting List Mortality of Liver Tumors
Division of Transplantation, Massachusetts General Hospital, Boston, MA
*Purpose: Liver transplantation has been approved for hepatocellular carcinoma (HCC), hilar cholangiocarcinoma (CCA) and metastatic neuroendocrine tumors (NET), with the aim to produce similar outcomes…2020 American Transplant Congress
Incidence of Skin Cancer – A Long Term Outcome of Immunosuppression in Renal Transplant Recipients Associated with the Usage of Azathioprine
*Purpose: The main cause of mortality in Kidney Transplant Recipient’s (KTRs) is malignancy. The cancer incidence is increased by treating with immunosuppressive agents and longer…2020 American Transplant Congress
Standardized Incidence of De Novo Hematological Malignancies after Liver Transplantation – A Meta-Analysis of Global Transplant Registries
*Purpose: Liver transplant (LT) recipients are at a higher risk of de novo malignancies. In this study we aim to study the distribution and incidence…2020 American Transplant Congress
Incidence and Outcomes of Secondary Cutaneous Malignancies among Renal Transplant Recipients
1Keck School of Medicine, LA, CA, 2Cedar Sinai Hospital, LA, CA
*Purpose: Solid-organ transplant recipients on immunosuppressive therapy are known to have higher morbidity and mortality from secondary malignancies; however, there are no established guidelines for…2020 American Transplant Congress
The Strategy and Utility of Checkpoint Inhibitor Therapy in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation
China Medical University Hospital, Taichung, Taiwan
*Purpose: Checkpoint inhibitor therapy is a hot and rapidly progressive therapy in advanced cancer patients in the past 2 years. Although some successful case report…2020 American Transplant Congress
Immune Checkpoint Inhibitor Use in Kidney Transplant Recipients: Rejection Risk, Prevention and Transcriptional Signature in Allograft
1Brigham and Women's Hospital, Boston, MA, 2University of Alberta, Edmonton, AB, Canada
*Purpose: Immune checkpoint inhibitor (ICI) use has changed the landscape of cancer treatment. Several cases of acute rejection in use of ICI have been reported,…2020 American Transplant Congress
Outcomes Following Deceased Donor Split/Partial Liver Transplant for Hepatocellular Carcinoma
Vanderbilt University Medical Center, Nashville, TN
*Purpose: To mitigate waiting time for liver transplant for hepatocellular carcinoma (HCC) and increase available organs, partial or split liver transplant (SLT) has been utilized.…2020 American Transplant Congress
Clinical Features and Transplant Outcomes in Kidney Transplant Recipients with Renal Cell Carcinoma
Asan Medical Center, Seoul, Korea, Republic of
*Purpose: Previous studies have recommended a 2-5-year waiting time prior to kidney transplantation (KT) in patients with end-stage renal disease (ESRD) and symptomatic renal cell…2020 American Transplant Congress
Multimodal Strategy for Hepatocellular Carcinoma in the Elderly: To Transplant or Not to Transplant
1Columbia University Irving Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
*Purpose: Liver transplantation LT for HCC is curative but entails increased risk and is limited by organ scarcity. Alternative approaches such as locoregional therapy (LRT)…2020 American Transplant Congress
Comparative Analysis of Risk Factors and Outcomes in Kidney Transplant Recipients with Lung Cancer and Those with No Malignancy: UNOS Data Set
*Purpose: Transplant recipients are at increased risk for malignancy. Patients who develop cancer after transplant have worse outcomes, especially those with lung cancer. Transplant-related risk…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 20
- Next Page »